Glenn Goddard - 30 Aug 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
30 Aug 2021
Net transactions value
-$4,213,959
Form type
4
Filing time
01 Sep 2021, 19:30:44 UTC
Previous filing
06 Aug 2021
Next filing
09 Sep 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise $100,204 +5,200 $19.27 5,200 30 Aug 2021 Direct
transaction NTLA Common Stock Sale $107,867 -704 -14% $153.22 4,496 30 Aug 2021 Direct F1, F2
transaction NTLA Common Stock Sale $169,719 -1,100 -24% $154.29 3,396 30 Aug 2021 Direct F1, F3
transaction NTLA Common Stock Sale $263,993 -1,700 -50% $155.29 1,696 30 Aug 2021 Direct F1, F4
transaction NTLA Common Stock Sale $46,830 -300 -18% $156.10 1,396 30 Aug 2021 Direct F1, F5
transaction NTLA Common Stock Sale $78,036 -496 -36% $157.33 900 30 Aug 2021 Direct F1, F6
transaction NTLA Common Stock Sale $47,526 -300 -33% $158.42 600 30 Aug 2021 Direct F1, F7
transaction NTLA Common Stock Sale $47,859 -300 -50% $159.53 300 30 Aug 2021 Direct F1, F8
transaction NTLA Common Stock Sale $48,252 -300 -100% $160.84 0 30 Aug 2021 Direct F1, F9
transaction NTLA Common Stock Options Exercise $442,882 +22,983 $19.27 22,983 31 Aug 2021 Direct
transaction NTLA Common Stock Options Exercise $26,492 +1,817 +7.9% $14.58 24,800 31 Aug 2021 Direct
transaction NTLA Common Stock Sale $3,973,456 -24,800 -100% $160.22 0 31 Aug 2021 Direct F1, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Options Exercise $0 -5,200 -7.4% $0.000000 64,800 30 Aug 2021 Common Stock 5,200 $19.27 Direct F11
transaction NTLA Stock Option (right to buy) Options Exercise $0 -22,983 -35% $0.000000 41,817 31 Aug 2021 Common Stock 22,983 $19.27 Direct F12
transaction NTLA Stock Option (right to buy) Options Exercise $0 -1,817 -10% $0.000000 15,933 31 Aug 2021 Common Stock 1,817 $14.58 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.75 to $153.62, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.76 to $154.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.805 to $155.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.81 to $156.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.86 to $157.84, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.08 to $158.81, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $159.79, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.61 to $160.95, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.59, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2021 at each separate price.
F11 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 30, 2021.
F12 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 31, 2021.
F13 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of August 31, 2021.